LUGPA 2023 Enduring CME Program: Turning Impossible to Possible: Solutions to Drive High Quality Care-LUGPA 2023 CME Program Part 4

Video Transcription

Video Summary

The session focused on active surveillance for prostate cancer, moderated by Dr. Ben Lowentritt, with a panel including experts like Dr. David Morris, Dr. Aaron Berger, Dr. Rani Abaza, and Dr. Dave Crawford. The discussion revolved around best practices for managing low to favorable intermediate-risk prostate cancer patients using active surveillance. They addressed concerns about overdiagnosis due to PSA screenings and debated appropriate candidates for active surveillance, emphasizing tailored approaches based on individual patient profiles, such as age, health, and genetic factors. <br /><br />Key points included utilizing genomic and imaging tests to identify and follow suitable candidates and the importance of monitoring patients to prevent missed progression. The panelists highlighted the role of shared decision-making with patients, discussing monitoring adherence, and when to transition from surveillance to treatment. They debated the appropriateness of continuing surveillance for certain patients, considering advancements like MRI and genetic testing, and the possibility of using 5-alpha reductase inhibitors to manage PSA levels. The goal is to avoid unnecessary treatments, ensuring interventions are timely when disease progression is evident.

Keywords

active surveillance

prostate cancer

PSA screening

genomic testing

shared decision-making

disease progression

5-alpha reductase inhibitors